Schizophrenia: References

1. Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Association between prenatal exposure to analgesics and risk of schizophrenia. Br J Psychiatry. 2004;185:366–371.

2. Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Do hypertension and diuretic treatment in pregnancy increase the risk of schizophrenia in offspring? American Journal of Psychiatry. 2003;160:464–468.

3. Byrne M, Agerbo E, Ewald H, Eaton WW, Mortensen PB. Parental age and risk of schizophrenia. Archives of General Psychiatry. 2003;60:673–678.

4. Sørensen HJ, Mortensen EL, Reinisch JM, Mednick SA. Breastfeeding and risk of schizophrenia in the Copenhagen Perinatal Cohort. Acta Psychiatr Scand. 2005;112:26–29.

5. Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am J Psychiatry. 2001;158:163–175.

6. Eckman TA, Wirshing WC, Marder SR, et al. Technique for training schizophrenic patients in illness self–management: a controlled trial. Am J Psychiatry. 1992;149:1549–1555.

7. Marder SR, Wirshing WC, Mintz J, et al. Two–year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am J Psychiatry. 1996;153:1585–1592.

8. Peet M. Diet, diabetes and schizophrenia: review and hypothesis. Br J Psychiatry. 2004;184(suppl 47):S102–S105.

9. Faulkner G, Soundy AA, Lloyd K. Schizophrenia and weight management: a systematic review of interventions to control weight. Acta Psychiatr Scand. 2003;108:324–332.

10. Mahadik SP, Evans D, Lal H. Oxidative stress and role of antioxidant and omega–3 essential fatty acid supplementation in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2001;25:463–493.

11. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry. 2001;62(suppl 27):15–26, discussion 40–41.

12. O'Keefe CD, Noordsy DL, Liss TB, Weiss H. Reversal of antipsychotic–associated weight gain. J Clin Psychiatry. 2003;64:907–912.

13. Chaldakov GN, Fiore M, Stankulov IS, et al. NGF, BDNF, leptin, and mast cells in human coronary atherosclerosis and metabolic syndrome. Arch Physiol Biochem. 2001;109:357–360.

14. Cohn T, Prud'homme D, Streiner D, Kameh H, Remington G. Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic syndrome. Can J Psychiatry. 2004;49:753–760.

15. Brown AS, Schaefer CA, Quesenberry CP Jr, Liu L, Babulas VP, Susser ES. Maternal exposure to toxoplasmosis and risk of schizophrenia in adult offspring.
Am J Psychiatry. 2005;162:767–773.

16. Torrey EF, Yolken RH. Toxoplasma gondii and Schizophrenia. Emerg Infect Dis. 2003;9:1375–1380.

17. Peet M. Nutrition and schizophrenia: beyond omega–3 fatty acids. Prostaglandins Leukot Essent Fatty Acids. 2004;70:417–422.

18. Richardson MA, Bevans ML, Read LL, et al. Efficacy of the branched–chain amino acids in the treatment of tardive dyskinesia in men. Am J Psychiatry. 2003;160:1117–1124.

19. Richardson MA, Small AM, Read LL, Chao HM, Clelland JD. Branched chain amino acid treatment of tardive dyskinesia in children and adolescents. J Clin Psychiatry. 2004;65:92–96.

20. Richardson MA, Bevans ML, Weber JB, et al. Branched chain amino acids decrease tardive dyskinesia symptoms. Psychopharmacology (Berl). 1999;143:358–364.